

**PRESCRIBING INFORMATION
PRODUCT MONOGRAPH**

Parsitan

Ethopropazine HCl

Antiparkinsonian Agent



8250 Décarie Blvd, suite 110
Montréal, QC
Canada, H4P 2P5

DATE OF PREPARATION:
November 26, 2002

DATE OF REVISION:

CONTROL NUMBER: 081125

Parsitan®

ERFA Canada 2012 Inc.
Ethopropazine HCl
Antiparkinsonian Agent

Indications: Symptomatic treatment of drug induced extrapyramidal manifestations and of Parkinson's disease of postencephalitic, arteriosclerotic or idiopathic etiology.

Contraindications: Glaucoma and hypersensitivity to phenothiazine drugs.

Precautions: Use with caution in patients with cardiac disease, prostatic hypertrophy or pyloric obstruction.

Adverse Effects: Drowsiness, dizziness, lassitude, blurred vision, dryness of mouth, paresthesia, headache. Very rarely, epigastric distress, confusion and ataxia.
Neuroleptic Malignant Syndrome: As with other neuroleptic drugs, a symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS) may occur. Cardinal features of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs), and evidence of autonomic instability (irregular pulse or blood pressure). Additional signs may include elevated CPK, myoglobinuria (rhabdomyolysis), and acute renal failure. NMS is potentially fatal and requires symptomatic treatment and immediate discontinuation of neuroleptic treatment.

Dosage: Must be adapted to each individual. In drug induced extrapyramidal reactions 100 mg twice daily usually brings about good control of symptoms. In post encephalitic, arteriosclerotic or idiopathic parkinsonism, initiate treatment at a low dose of 50 mg 3 times a day and increase from 50 to 100 mg daily every 2 to 3 days until the optimum effect is obtained or the limit of tolerance is attained. Drowsiness and anticholinergic effects which may appear at the beginning of treatment generally subside after a few days. The normal daily dose usually ranges between 100 and 500 mg but it may reach 1 g or more per day in certain patients.

Supplied: Each biconvex white tablet is not embossed and has a diameter of 8mm containing: ethopropazine base 50 mg (as the hydrochloride). Nonmedicinal ingredients: acetic anhydride, carnauba wax, cellulose, colloidal silicon dioxide, dicalcium phosphate, diethyl phthalate, magnesium stearate, sodium croscarmellose, sodium oleate, titanium oxide and zein. Tartrazine-free. Bottles of 100.